# OnCo record keynote-412 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/keynote-412/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "keynote-412", "NCT03040999" ;
  schema:name "KEYNOTE-412"@en ;
  schema:description "KEYNOTE-412 tested adding pembrolizumab to standard chemoradiotherapy for locally advanced head and neck cancer; the improvement in keeping patients free of disease fell short of statistical significance, so chemoradiotherapy alone remains the standard."@en ;
  schema:url <https://onco.cc/trials/keynote-412/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03040999> ;
  onco:status "negative" ;
  onco:tag "subtype-trials" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/hpv-negative-head-and-neck-cancer/>, <https://onco.cc/cancers/head-and-neck/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/merck/> ;
  onco:people <https://onco.cc/people/jean-pascal-machiels/> .